MX2019003895A - Compuestos y metodos para activar la señalizacion tie2. - Google Patents
Compuestos y metodos para activar la señalizacion tie2.Info
- Publication number
- MX2019003895A MX2019003895A MX2019003895A MX2019003895A MX2019003895A MX 2019003895 A MX2019003895 A MX 2019003895A MX 2019003895 A MX2019003895 A MX 2019003895A MX 2019003895 A MX2019003895 A MX 2019003895A MX 2019003895 A MX2019003895 A MX 2019003895A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- compounds
- tie2
- peptides
- tie2 signaling
- Prior art date
Links
- 101100481408 Danio rerio tie2 gene Proteins 0.000 title abstract 4
- 230000003213 activating effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 230000011664 signaling Effects 0.000 title 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 102000008186 Collagen Human genes 0.000 abstract 2
- 108010035532 Collagen Proteins 0.000 abstract 2
- 230000003592 biomimetic effect Effects 0.000 abstract 2
- 229920001436 collagen Polymers 0.000 abstract 2
- 230000008728 vascular permeability Effects 0.000 abstract 2
- 108010048036 Angiopoietin-2 Proteins 0.000 abstract 1
- 102000009075 Angiopoietin-2 Human genes 0.000 abstract 1
- 102100034608 Angiopoietin-2 Human genes 0.000 abstract 1
- 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000001365 lymphatic vessel Anatomy 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
- 210000005166 vasculature Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
- A61K47/6937—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol the polymer being PLGA, PLA or polyglycolic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662403786P | 2016-10-04 | 2016-10-04 | |
| PCT/US2017/055055 WO2018067646A1 (en) | 2016-10-04 | 2017-10-04 | Compounds and methods for activating tie2 signaling |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019003895A true MX2019003895A (es) | 2019-10-07 |
Family
ID=61832135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019003895A MX2019003895A (es) | 2016-10-04 | 2017-10-04 | Compuestos y metodos para activar la señalizacion tie2. |
Country Status (14)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2828739T3 (es) | 2006-04-07 | 2021-05-27 | Aerpio Pharmaceuticals Inc | Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos |
| US20130095065A1 (en) | 2011-10-13 | 2013-04-18 | Aerpio Therapeutics, Inc. | Methods for Treating Vascular Leak Syndrome and Cancer |
| AU2018266690A1 (en) * | 2017-05-08 | 2019-12-12 | Asclepix Therapeutics, Inc. | Biodegradable microparticles for sustained delivery of anti-angiogenic peptide |
| EP3661536A4 (en) | 2017-08-03 | 2021-07-21 | Asclepix Therapeutics, Inc. | PROCESSES FOR IDENTIFYING AND PREPARING PHARMACEUTICAL AGENTS TO ACTIVATE THE TIE2 RECEPTOR |
| EP3856245A4 (en) | 2018-09-24 | 2022-10-26 | EyePoint Pharmaceuticals, Inc. | MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - ß (VE-PTP) AND VEGF |
| KR20210146352A (ko) * | 2019-03-26 | 2021-12-03 | 아스클리픽스 테라퓨틱스, 인크. | 안구 질환 치료용 조성물 및 방법 |
| CN117126233A (zh) * | 2022-05-20 | 2023-11-28 | 杭州禾泰健宇生物科技有限公司 | 一种类肽化合物及其应用 |
| WO2024044745A2 (en) * | 2022-08-26 | 2024-02-29 | Asclepix Therapeutics, Inc. | Formulations for intraocular delivery of peptides derived from type iv collagen |
| KR20240133892A (ko) * | 2023-02-28 | 2024-09-05 | 주식회사 파멥신 | 전신 모세혈관 누출 증후군의 예방 또는 치료용 조성물 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU663053B2 (en) | 1990-06-11 | 1995-09-28 | Gilead Sciences, Inc. | Nucleic acid ligands |
| SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
| EP1405911A1 (en) | 1994-07-20 | 2004-04-07 | The General Hospital Corporation | Interaction trap systems for detecting protein interactions |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| ATE320486T1 (de) | 1999-05-05 | 2006-04-15 | Phylogica Ltd | Isolierung von biologischen modulatoren aus bibiotheken mit biologisch vielfältigen genfragmenten |
| AU4761100A (en) | 1999-05-26 | 2000-12-18 | Kalle Saksela | Methods and materials for generating sh3 domains with tailored binding properties |
| SE0001877D0 (sv) | 2000-05-22 | 2000-05-22 | Klaus Mosbach | Molecular imprinting |
| ES2335861T3 (es) | 2000-09-08 | 2010-04-06 | Universitat Zurich | Grupos de proteinas repetitivas que comprenden modulos repetitivos. |
| DE10053224A1 (de) | 2000-10-26 | 2002-05-08 | Univ Goettingen Georg August | Verfahren zur Exposition von Peptiden und Polypeptiden auf der Zelloberfläche von Bakterien |
| EP2284270A3 (en) | 2000-12-13 | 2012-07-25 | Anaphore, Inc. | Method for the identification and isolation of binding polypeptides from combinatorial libraries of proteins having the scaffold structure of C-type lectin-like domains |
| MXPA04001804A (es) | 2001-08-30 | 2005-03-07 | Biorexis Pharmaceutical Corp | Proteinas de fusion de transferrina modificada. |
| AU2003282724B2 (en) | 2002-10-02 | 2010-03-04 | Catalyst Biosciences, Inc. | Methods of generating and screening for proteases with altered specificity |
| PT1587907E (pt) | 2003-01-07 | 2011-04-08 | Dyax Corp | Biblioteca de domínios de kunitz |
| US20060008844A1 (en) | 2004-06-17 | 2006-01-12 | Avidia Research Institute | c-Met kinase binding proteins |
| DE102004049479A1 (de) | 2004-10-11 | 2006-04-13 | Scil Proteins Gmbh | Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie |
| WO2007033215A2 (en) * | 2005-09-12 | 2007-03-22 | The Johns Hopkins University | Compositions having antiangiogenic activity and uses thereof |
| EP1892248A1 (en) | 2006-08-21 | 2008-02-27 | Eidgenössische Technische Hochschule Zürich | Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase |
| KR101580937B1 (ko) | 2007-06-01 | 2015-12-31 | 유니버시티 오브 매릴랜드, 발티모어 | 면역글로불린 불변영역 Ｆｃ 수용체 결합제 |
| AR070032A1 (es) * | 2007-11-09 | 2010-03-10 | Genentech Inc | Composiciones y metodos de uso de antagonistas quinasa-1 similar al receptor de la activina (alk-1) |
| US9051349B2 (en) | 2007-11-21 | 2015-06-09 | Alba Therapeutics Corporation | Larazotide acetate compositions |
| CN103495170A (zh) * | 2009-07-07 | 2014-01-08 | 诺尔姆奥克西斯公司 | 使用肌醇三焦磷酸减少多药抗性的方法 |
| EP2649095B1 (en) | 2010-12-10 | 2021-10-06 | Aleksander S. Popel | Mimetic peptides derived from collagen type iv and their use for treating angiogenesis- and lymphangiogenesis- dependent diseases |
| EP2788473A4 (en) | 2011-12-09 | 2015-11-11 | Univ Johns Hopkins | ARTIFICIAL ANTIGEN PRESENTING CELLS WITH DEFINED AND DYNAMIC FORM |
| CA2914764C (en) | 2013-06-07 | 2021-10-26 | The Johns Hopkins University | A biomimetic peptide and biodegradable delivery platform for the treatment of angiogenesis-and lymphangiogenesis-dependent diseases |
-
2017
- 2017-10-04 SG SG10202103032QA patent/SG10202103032QA/en unknown
- 2017-10-04 AU AU2017339970A patent/AU2017339970A1/en not_active Abandoned
- 2017-10-04 CN CN201780074408.5A patent/CN110177563A/zh active Pending
- 2017-10-04 MX MX2019003895A patent/MX2019003895A/es unknown
- 2017-10-04 JP JP2019517873A patent/JP2019535651A/ja active Pending
- 2017-10-04 EA EA201990868A patent/EA201990868A1/ru unknown
- 2017-10-04 WO PCT/US2017/055055 patent/WO2018067646A1/en not_active Ceased
- 2017-10-04 US US16/336,777 patent/US20190225670A1/en not_active Abandoned
- 2017-10-04 EP EP17859077.4A patent/EP3522906B1/en active Active
- 2017-10-04 BR BR112019006735A patent/BR112019006735A2/pt not_active Application Discontinuation
- 2017-10-04 KR KR1020197012909A patent/KR20190066040A/ko not_active Ceased
- 2017-10-04 CA CA3038809A patent/CA3038809A1/en not_active Abandoned
-
2019
- 2019-03-28 IL IL265694A patent/IL265694A/en unknown
- 2019-04-12 ZA ZA2019/02344A patent/ZA201902344B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3522906A4 (en) | 2020-06-10 |
| AU2017339970A1 (en) | 2019-04-18 |
| CN110177563A (zh) | 2019-08-27 |
| JP2019535651A (ja) | 2019-12-12 |
| BR112019006735A2 (pt) | 2019-06-25 |
| IL265694A (en) | 2019-05-30 |
| EA201990868A1 (ru) | 2019-09-30 |
| CA3038809A1 (en) | 2018-04-12 |
| US20190225670A1 (en) | 2019-07-25 |
| KR20190066040A (ko) | 2019-06-12 |
| EP3522906B1 (en) | 2022-03-23 |
| EP3522906A1 (en) | 2019-08-14 |
| WO2018067646A1 (en) | 2018-04-12 |
| ZA201902344B (en) | 2021-09-29 |
| SG10202103032QA (en) | 2021-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019003895A (es) | Compuestos y metodos para activar la señalizacion tie2. | |
| MD4801B1 (ro) | Antagonişti ai activin-ActRII şi utilizarea lor pentru tratamentul sindroamelor mielodisplazice | |
| MX2021006017A (es) | Polipeptidos de folistatina y sus usos. | |
| MX2019013289A (es) | Variantes de ligasa modificadas geneticamente. | |
| MD3313423T2 (ro) | Compoziții care conțin tulpini bacteriene de Blautia pentru tratamentul hipersensibilității viscerale | |
| MX370689B (es) | Polipeptidos apelina. | |
| MX2017001288A (es) | Composicion para el tratamiento de telas que comprende una nanoemulsion de polimero de aminosiloxano. | |
| PH12019502002A1 (en) | Combination theraphy | |
| MX2022014634A (es) | Metodos para la administracion linfatica de agentes activos. | |
| MX2018002546A (es) | Composiciones que comprenden un compuesto de urolitina. | |
| MX2019007152A (es) | Peptido novedoso. | |
| MX382778B (es) | Metodos para tratar cancer pancreatico | |
| MD4628B1 (ro) | Procedeu de obţinere a unei soluţii stabile injectabile cu concentraţie redusă de noradrenalină | |
| PH12018501279A1 (en) | Compositions comprising 15-hepe and methods of using the same | |
| MX2018006194A (es) | Peptidos con propiedades antiangiogenicas, antilinfangiogenicas y antiedemicas y formulaciones de nanoparticulas. | |
| PH12021550122A1 (en) | Solubilized apyrases, methods and use | |
| MY192577A (en) | Ophthalmic solution comprising epinastine | |
| SG11201804160SA (en) | Composition for inhibiting carnosine dipeptidase | |
| PH12017501549A1 (en) | Peptides for inhibiting angiogenesis | |
| BR112017023762A2 (pt) | formulações de depósito injetáveis | |
| MX383947B (es) | Composiciones de colágeno 7 y métodos para usar las mismas. | |
| MA40642A (fr) | Nouveaux dérivés peptidiques et leurs utilisations | |
| MX2020013410A (es) | Proteinas prohemostaticas para el tratamiento de hemorragias. | |
| NZ734845A (en) | Use of short synthetic peptide for the treatment and/or prophylaxis of dry eye disease | |
| AR104194A1 (es) | Composición del factor de von willebrand |